Summary
Explore the Global API Market, valued at USD 207.5 billion and projected to reach USD 314.3 billion by 2029, with trends, forecast and competitive insights.
Market Overview
Global API Market Overview
The Global API Market was valued at USD 160.4 Bn in 2018 and grew at a CAGR of 5.3% during 2018–2023. The market is further anticipated to reach USD 314.3 Bn by 2029, expanding at a projected CAGR of 7.2% during the forecast period of 2023–2029. Structurally, the market remains moderately fragmented, with the presence of several large and established players. Growth in the market is being driven by higher pharmaceutical demand following the 2020–2021 pandemic period, which accelerated research and development activity, along with the expansion of API manufacturers in selected regions benefiting from economies of scale.
Taxonomy
Global API Market Ecosystem
Global API Market (in USD Mn), 2018-2023
The current Active Pharmaceutical Ingredient (API) market has grown at a CAGR of 5.3%, reaching a market size of USD 207.5 Bn in 2023. This growth has been primarily supported by the rising number of API manufacturers in the Asia-Pacific region, driven by greater ease of doing business and lower operating costs, particularly in China. The market, however, experienced a slowdown in 2020, with growth declining from 5.1% to 4.5%, mainly due to supply chain disruptions caused by nationwide restrictions imposed to contain COVID-19. At the same time, the pandemic also created excess demand for medicines, and alongside the rising prevalence of diseases, this contributed to stronger demand growth in 2020 and 2021.
Global API Market Industry Analysis
Global API Market Segmentation, 2023
Global API Market by Business Mode (in revenue %)
Most Active Pharmaceutical Ingredient (API) manufacturers operate under the captive business mode, which accounted for 77% of the market in 2023, valued at USD 159.8 Bn. In comparison, the merchant API segment contributed 23% of total revenue during the same year, despite a growing trend among companies to outsource manufacturing in order to reduce costs and avoid investment in expensive equipment and sophisticated infrastructure. The growth of the merchant API market is being supported by the increasing importance of generic drugs, technological advancements in API manufacturing, and capacity expansion initiatives by pharmaceutical and biopharmaceutical companies.
Global API Market by Type (in revenue %), 2023
Synthetic APIs accounted for 72% of the revenue share of the Active Pharmaceutical Ingredient market, valued at USD 149.9 Bn, while Natural APIs constituted the remaining 28% share, valued at USD 58.1 Bn. Synthetic APIs dominate the market due to their ease of manufacturing, affordability, and convenience, as chemical synthesis makes them easier to produce and often less expensive than natural counterparts. In addition, synthetic APIs provide greater control over the manufacturing process, enabling more consistent quality and purity, while also offering better stability and longer shelf life, which supports scalability. Although synthetic APIs remain the dominant segment, natural APIs are expected to witness faster growth, driven by increasing investments in biopharmaceuticals that are enabling the development of new molecules for diseases such as cancer.
Global API Future Market Size
The Global API Market is anticipated to grow at a CAGR of 7.2%, increasing in value from USD 207.5 Bn in 2023 to USD 314.3 Bn by 2029. This growth is expected to be driven by factors such as increasing global healthcare needs, stronger pandemic preparedness and response capabilities, and supportive regulatory frameworks. In addition, the forecast period is likely to witness stronger momentum in Natural or Large Molecule APIs, as major companies such as Merck, Pfizer, and Teva continue to explore treatments and cures for chronic diseases.
Global API Market Company Profile
| Company Name | Establishment year | Description |
|---|---|---|
The Merck Group | 1668 | The first pharmaceutical company in the world, founded by Friedrich Jacob Merck in Germany, has transformed into a Science and Technology company. Around 83% of the company’s total revenue is generated from life sciences and healthcare, while the remaining 17% comes from electronics (2022). The Life Science business is research-driven and innovation-focused. In 2016, the company invested EUR 260 million in R&D, enabling the launch of 2,100 new innovative products, developed to meet customers’ unmet needs ranging from antibodies to water purification systems. |
AstraZeneca plc | 1999 | AstraZeneca Plc is a holding company engaged in the research, development, and manufacturing of pharmaceutical products. Its pipeline focuses on therapy areas including oncology, cardiovascular, renal, metabolism, and respiratory diseases. Founded on June 17, 1992, the company is headquartered in Cambridge, United Kingdom. AstraZeneca is a global science-led, patient-focused pharmaceutical company committed to transforming the future of healthcare by unlocking the power of science for people, society, and the planet. |
Teva Pharmaceutical Industries Ltd. | 1901 | Teva’s portfolio of around 3,600 products is among the largest in the pharmaceutical industry. Nearly 200 million people in 60 countries benefit from Teva medicines every day. Teva API supplies high-quality APIs to over 1,000 customers worldwide. Its portfolio includes more than 400 APIs manufactured across 16 advanced production facilities, employing over 5,000 highly trained professionals. Teva remains committed to environmental, health, and safety (EHS) standards to ensure sustainable production. |
Pfizer Inc. | 1849 | Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was founded in 1849 by Charles Pfizer and Charles F. Erhart. Pfizer currently operates in 181 countries, delivering over 80 million doses of medicines and vaccines and reaching approximately 1.3 billion patients worldwide, equivalent to 1 out of every 6 people globally. |
Global API Market Macro Indicators
The dependency ratio is defined as the number of children and older persons per hundred persons of working age. In 2022, the ratio was at 54% and is projected to grow to around 60% by 2050.The elderly population is one of the main recipients of health care, and with the increase in their numbers the demand for availing medical care, and hence the medicines would also grow.
The Outlook projects global GDP growth of 2.9% in 2023, followed by a mild slowdown to 2.7% in 2024 and a slight improvement to 3.0% in 2025. Asia is expected to continue to account for the bulk of global growth in 2024-25, as it has in 2023. Moreover taking a subset of World’ GDP, the G20 economies; Asia-Pacific is anticipated to drive the GDP growth of the world
With the rise in Inflation in the global scenario, the cost of availing raw material, energy cost and others facilities, leads to a hike in operational cost of the companies. As most of the raw material for the manufacturing of API and henceforth medicine are imported from the APAC region to rest of the world. Therefore, an increase in inflation could have a detrimental effect on the growth of Global API Market. However, a decline in inflation would have an opposite effect.
Frequently Asked Questions
Find quick answers to common questions about the Global API Market